THEMIS MEDICARE LIMITED (THEMISMED): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹101.58 latest close · −14.3% over the last 90 sessions

₹101.58 month-end · −5.8% over 12 months

₹101.58 month-end · −40.5% over 3 years

₹101.58 month-end · +255.2% since Jan '19

52-week range ₹64.95 to ₹140.60 · 1-year volatility 52.1%

Was the rally earned?

3 years5 years

-41%share price, 3 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 27 points, while the multiple moved less (P/E 27.6x to 23.4x).
The share count barely moved.

Net profit growth-27 ptsNet profit fell about 30%, which lowers the price.

P/E change-13 ptsThe P/E fell from 27.6x to 23.4x, which lowers the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

+12%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

Per-share earnings added 12 points, but investors now pay less per rupee of profit (P/E 23.5x to 23.4x), which took 0 points back.
The share count barely moved.

Net profit growth+11 ptsNet profit rose about 11%, which lifts the price.

P/E change0 ptsThe P/E fell from 23.5x to 23.4x, which lowers the price.

Share count change+1 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 1 year: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-78.0%not yet recovered

1-year volatility52.1%annualised

Beta vs sector index1.523-year daily, correlation 0.40

Volume spikes6last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-78.0% (2024-12 peak to 2026-03 low, not yet recovered)

-57.3% (2019-01 peak to 2019-08 low, recovered 2020-01)

-48.0% (2020-02 peak to 2020-03 low, recovered 2021-05)

Most recent volume spikes

2026-09-30: 5.7x the 50-day median, price -2.9% that day

2026-09-07: 56.8x the 50-day median, price +10.5% that day

2026-08-26: 22.2x the 50-day median, price +5.9% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

23.4xP/E todayWithin its usual range

Against its own history43rd percentile

CheapestMedian 23.9xDearest

Usual range 12.4x to 47.5x since 2019-01.

Against Health Technology23.4x vs 37.0x

This company

23.4x

Sector median

37.0x

37% below the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE16th▼ 17 pts vs a year ago
Op. margin4thflat vs a year ago
Revenue growth6th▼ 5 pts vs a year ago
EPS growth12thflat vs a year ago
Debt/equity ↓49th▼ 3 pts vs a year ago
Cash cycle ↓17thflat vs a year ago
P/E ↓72nd
12M momentum32nd▲ 29 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~16%annual earnings growth implied by the price

At a P/E of 22.8x, the price would imply about 16.1%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹101.58
P/E: 23.4x
ROCE: 3.0%
Market Cap: ₹935 cr
Revenue (TTM): ₹332 cr
P/S: 2.8x
P/B: 2.4x
ROE: 10.1%
Operating Margin: -60.0%
Debt / Equity: 0.3x
Promoter Holding: 67.1%
12M Momentum: -5.8%

52-week range

₹64.95₹140.60

48% of the way from its 52-week low to its high

Price risk

1Y volatility

52.1%

Beta vs sector

1-year daily

1.82

Balance sheet & cash

Interest cover

operating profit ÷ interest

5.5x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.72x

Share count, 1Y

unchanged

Are profits backed by cash?

2 of 7checks within range1 beyond a threshold

Other income reliance216%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 216.4%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate13%Near threshold

Median quarterly effective tax rate over about 2.5 years: 12.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.72xNear threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.72x (cash from operations ₹54 cr, net profit ₹75 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+31 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 31 days (190 vs 159). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress1% of fixed assetsWithin range

Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+17 days / 2 yrsWithin range

Days payable changed by +17 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, institutional and promoter holdings were broadly unchanged.
The number of shareholders rose from 6,970 to 21,267 (+205%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters67.2%67.1%-0.1 pts

FIIs0.1%0.0%0.0 pts

DIIs0.0%0.0%0.0 pts

Public and others32.8%32.9%+0.1 pts

Number of shareholders

21,267shareholders+205% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+17.3%typical 12-month return vs the marketAbove the base rate

We found 50 past situations where a non-financial company looked like THEMIS MEDICARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −13% to +39% vs the market, against +1% for all non-financial companies in the same months.
The analogs' median sat above that base rate (gap +16.2%, 80% range +0.1% to +20.9%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 7 beyond the range shown, drawn at the edge

Similar setups' median

+17.3%

All companies' median

+1.1%

Beat the market

62% vs 51%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ANANTRAJ Consumer Durables	Oct 2020	20x	1%	−2%	−21%	+112%
SRHHYPOLTD Process Industries	Feb 2020	22x	4%	−11%	−31%	+36%
NELCAST Non-Energy Minerals	Jan 2021	16x	7%	+34%	−15%	−11%
GUJAPOLLO Producer Manufacturing	Oct 2024	32x	3%	+48%	−20%	+40%
NEULANDLAB Health Technology	Jan 2023	30x	10%	0%	−24%	+211%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
KAKATCEM Non-Energy Minerals	May 2020	21x	3%	−30%	−50%	0%
AGI Process Industries	Aug 2025	18x	—	−6%	−31%	−19%
JAICORPLTD Process Industries	Apr 2022	28x	4%	+66%	−15%	+5%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to THEMIS MEDICARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

VISA CHROMEVISACHROME

Non-Energy Minerals

72%similar

volatilityrevenue

PRECISION CAMSHAFTSPRECAM

Producer Manufacturing

70%similar

P/Emarket cap

ORIENT BELLORIENTBELL

Producer Manufacturing

69%similar

promoter holdingP/E

TRANSWORLD SHIPPING LINESTRANSWORLD

Transportation

68%similar

operating marginrevenue

STERLING TOOLSSTERTOOLS

Producer Manufacturing

67%similar

debt/equitymarket cap

BAFNA PHARMACEUTICALSBAFNAPH

Health Technology

49%similar

market caprevenue growth

HIKALHIKAL

Health Technology

40%similar

ROCEvolatility

KOPRANKOPRAN

Health Technology

40%similar

volatilitydebt/equity

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jul '23

2026
SepPriceVolume reached 56.8x its 50-day median on 2026-09-07; price +10.5% that day.
JunResultsEPS (TTM) turned positive.
JunValuationP/E crossed above the 90th percentile of its own history to date (782.5x).
JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
JunPriceVolume reached 104.1x its 50-day median on 2026-06-23; price +3.3% that day.
MarPriceFell 78% from the Dec 2024 peak to the Mar 2026 low.
MarPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
MarPriceVolume reached 13.3x its 50-day median on 2026-03-09; price -2.5% that day.

Show 22 earlier events

2025
OctPriceVolume reached 142.4x its 50-day median on 2025-10-09; price +11.0% that day.
SepResultsEPS (TTM) turned negative.
AugPriceVolume reached 46.2x its 50-day median on 2025-08-06; price +11.2% that day.
JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
MayPriceVolume reached 7.2x its 50-day median on 2025-05-19; price +13.0% that day.
MarPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
MarPriceVolume reached 7.0x its 50-day median on 2025-03-24; price +2.9% that day.
2024
DecPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the top quartile).
NovPriceVolume reached 12.3x its 50-day median on 2024-11-18; price +5.1% that day.
SepResultsRevenue (TTM) reached a new high of ₹409 cr.
SepPeer rankMoved into the top quartile of Health Technology on operating margin (from the bottom quartile).
SepPriceVolume reached 26.0x its 50-day median on 2024-09-12; price +9.9% that day.
JulPriceRegained the 2024-03 peak, 1 month after the low.
JunPriceFell 26% from the Mar 2024 peak to the Jun 2024 low.
JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
JanPriceVolume reached 12.3x its 50-day median on 2024-01-05; price +0.4% that day.
2023
DecPriceRegained the 2023-10 peak, 1 month after the low.
DecPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
NovPriceFell 25% from the Oct 2023 peak to the Nov 2023 low.
OctPriceVolume reached 16.7x its 50-day median on 2023-10-03; price +6.2% that day.
AugValuationP/E crossed above the 90th percentile of its own history to date (25.5x).
JulPriceVolume reached 8.7x its 50-day median on 2023-07-05; price +5.5% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	23.4x	₹332 cr	10.1%	3.0%	0.3x
2026-10	21.8x	₹332 cr	10.1%	3.0%	0.3x
2026-09	26.8x	₹332 cr	10.1%	3.0%	0.3x
2026-08	891.1x	₹343 cr	0.3%	3.0%	0.3x
2026-07	751.6x	₹343 cr	0.3%	3.0%	0.3x
2026-06	782.5x	₹343 cr	0.3%	3.0%	0.3x
2026-05	—	₹338 cr	-4.5%	10.0%	0.2x
2026-04	—	₹338 cr	-4.5%	10.0%	0.2x
2026-03	—	₹338 cr	-4.5%	10.0%	0.2x
2026-02	—	₹342 cr	-6.7%	10.0%	0.2x
2026-01	—	₹342 cr	-6.7%	10.0%	0.2x
2025-12	—	₹342 cr	-6.7%	10.0%	0.2x
2025-11	—	₹381 cr	-2.2%	10.0%	0.2x
2025-10	—	₹381 cr	-2.2%	10.0%	0.2x
2025-09	—	₹381 cr	-2.2%	10.0%	0.2x
2025-08	30.6x	₹406 cr	7.5%	10.0%	0.2x
2025-07	33.2x	₹406 cr	7.5%	10.0%	0.2x
2025-06	40.1x	₹406 cr	7.5%	10.0%	0.2x
2025-05	27.1x	₹432 cr	12.5%	14.0%	0.3x
2025-04	25.8x	₹432 cr	12.5%	14.0%	0.3x
2025-03	29.3x	₹432 cr	12.5%	14.0%	0.3x
2025-02	27.5x	₹421 cr	14.1%	14.0%	0.3x
2025-01	39.5x	₹421 cr	14.1%	14.0%	0.3x
2024-12	45.8x	₹421 cr	14.1%	14.0%	0.3x
2024-11	53.9x	₹409 cr	13.3%	14.0%	0.3x
2024-10	48.2x	₹409 cr	13.3%	14.0%	0.3x
2024-09	50.3x	₹409 cr	13.3%	14.0%	0.3x
2024-08	53.4x	₹383 cr	11.4%	14.0%	0.3x
2024-07	53.1x	₹383 cr	11.4%	14.0%	0.3x
2024-06	44.3x	₹383 cr	11.4%	14.0%	0.3x
2024-05	32.8x	₹354 cr	16.8%	20.0%	0.3x
2024-04	35.7x	₹354 cr	16.8%	20.0%	0.3x
2024-03	35.4x	₹354 cr	16.8%	20.0%	0.3x
2024-02	38.3x	₹354 cr	16.8%	20.0%	0.3x
2024-01	39.0x	₹354 cr	16.8%	20.0%	0.3x
2023-12	34.6x	₹354 cr	16.8%	20.0%	0.3x
2023-11	27.6x	₹354 cr	16.8%	20.0%	0.3x
2023-10	25.1x	₹354 cr	16.8%	20.0%	0.3x
2023-09	29.3x	₹354 cr	16.8%	20.0%	0.3x
2023-08	25.5x	₹354 cr	16.8%	20.0%	0.3x
2023-07	23.6x	₹354 cr	16.8%	20.0%	0.3x
2023-06	22.0x	₹354 cr	16.8%	20.0%	0.3x
2023-05	18.6x	₹395 cr	25.4%	30.0%	0.3x
2023-04	19.8x	₹395 cr	25.4%	30.0%	0.3x
2023-03	14.9x	₹395 cr	25.4%	30.0%	0.3x
2023-02	15.1x	₹395 cr	25.4%	30.0%	0.3x
2023-01	16.0x	₹395 cr	25.4%	30.0%	0.3x
2022-12	17.1x	₹395 cr	25.4%	30.0%	0.3x
2022-11	12.6x	₹395 cr	25.4%	30.0%	0.3x
2022-10	12.4x	₹395 cr	25.4%	30.0%	0.3x
2022-09	12.9x	₹395 cr	25.4%	30.0%	0.3x
2022-08	10.4x	₹395 cr	25.4%	30.0%	0.3x
2022-07	9.8x	₹395 cr	25.4%	30.0%	0.3x
2022-06	9.4x	₹395 cr	25.4%	30.0%	0.3x
2022-05	20.2x	₹231 cr	16.5%	18.0%	0.4x
2022-04	23.8x	₹231 cr	16.5%	18.0%	0.4x
2022-03	24.1x	₹231 cr	16.5%	18.0%	0.4x
2022-02	25.4x	₹231 cr	16.5%	18.0%	0.4x
2022-01	25.3x	₹231 cr	16.5%	18.0%	0.4x
2021-12	24.3x	₹231 cr	16.5%	18.0%	0.4x
2021-11	23.5x	₹231 cr	16.5%	18.0%	0.4x
2021-10	21.1x	₹231 cr	16.5%	18.0%	0.4x
2021-09	25.9x	₹231 cr	16.5%	18.0%	0.4x
2021-08	29.3x	₹231 cr	16.5%	18.0%	0.4x
2021-07	23.8x	₹231 cr	16.5%	18.0%	0.4x
2021-06	18.0x	₹231 cr	16.5%	18.0%	0.4x
2021-05	21.4x	₹202 cr	13.7%	15.0%	0.5x
2021-04	13.8x	₹202 cr	13.7%	15.0%	0.5x
2021-03	10.4x	₹202 cr	13.7%	15.0%	0.5x
2021-02	11.4x	₹202 cr	13.7%	15.0%	0.5x
2021-01	12.2x	₹202 cr	13.7%	15.0%	0.5x
2020-12	13.4x	₹202 cr	13.7%	15.0%	0.5x
2020-11	12.9x	₹202 cr	13.7%	15.0%	0.5x
2020-10	11.9x	₹202 cr	13.7%	15.0%	0.5x
2020-09	13.3x	₹202 cr	13.7%	15.0%	0.5x
2020-08	13.7x	₹202 cr	13.7%	15.0%	0.5x
2020-07	14.4x	₹202 cr	13.7%	15.0%	0.5x
2020-06	12.7x	₹202 cr	13.7%	15.0%	0.5x
2020-05	—	₹184 cr	-7.0%	-1.0%	0.5x
2020-04	—	₹184 cr	-7.0%	-1.0%	0.5x
2020-03	—	₹184 cr	-7.0%	-1.0%	0.5x
2020-02	—	₹184 cr	-7.0%	-1.0%	0.5x
2020-01	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-12	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-11	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-10	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-09	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-08	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-07	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-06	—	₹184 cr	-7.0%	-1.0%	0.5x
2019-05	22.1x	₹210 cr	6.5%	10.0%	0.5x
2019-04	23.6x	₹210 cr	6.5%	10.0%	0.5x
2019-03	24.0x	₹210 cr	6.5%	10.0%	0.5x
2019-02	24.0x	₹210 cr	6.5%	10.0%	0.5x
2019-01	23.3x	₹210 cr	6.5%	10.0%	0.5x

Methodology and data notes